MCRB Seres Therapeutics Inc.

5.9
+0.07  (+1%)
Previous Close 5.83
Open 5.89
Price To Book -7.87
Market Cap 241049863
Shares 40,855,909
Volume 66,074
Short Ratio
Av. Daily Volume 112,128

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1b trial showed no relevant difference in risk of recurrence compared to placebo - company did note was not powered to detect a statistically significant difference in recurrence rates.
SER-262
Primary Clostridium Difficile infection (CDI)
Phase 3 trial initiation announced June 12, 2017. Noted February 7, 2019 that the trial continues to enrol but is evaluating modification of the trial to expedite clinical results.
SER-109 - ECOSPOR III
Recurrent C. Difficile infection
Phase 2b trial initiation announced January 3, 2019.
SER-287
Mild-to-Moderate Ulcerative Colitis

Latest News

  1. Seres Therapeutics Announces Corporate Changes to Focus on Advancing Clinical Assets
  2. Seres Therapeutics Announces Chief Executive Officer Transition
  3. Does Seres Therapeutics, Inc.’s (NASDAQ:MCRB) CEO Salary Compare Well With Others?
  4. Seres Therapeutics Announces Initiation of SER-287 Phase 2B ECO-RESET Clinical Study for Ulcerative Colitis
  5. Research Report Identifies OraSure Technologies, Sierra Wireless, Seres Therapeutics, Lydall, ChromaDex, and Capricor Therapeutics with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  6. Edited Transcript of MCRB earnings conference call or presentation 8-Nov-18 1:30pm GMT
  7. Seres Therapeutics to Present at the Stifel 2018 Healthcare Conference
  8. Seres Therapeutics (MCRB) Reports Q3 Loss, Misses Revenue Estimates
  9. Seres Therapeutics Reports Third Quarter Financial Results and Provides Operational Updates
  10. Seres Therapeutics to Host Third Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on November 8, 2018
  11. Seres Therapeutics Announces Appointment of Kevin Horgan, M.D., as Chief Medical Officer
  12. Seres Therapeutics Sees Hammer Chart Pattern: Time to Buy?
  13. Seres Therapeutics to Present New Data Supporting SER-109 Clinical Activity at IDWeek 2018
  14. The Microbiome Therapeutics Innovation Group Announces Coalition Formation and Leadership Team
  15. Edited Transcript of MCRB earnings conference call or presentation 2-Aug-18 12:30pm GMT
  16. Seres Therapeutics (MCRB) Reports Q2 Loss, Lags Revenue Estimates
  17. Seres Therapeutics: 2Q Earnings Snapshot
  18. Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates

SEC Filings

  1. SC 13G - Statement of acquisition of beneficial ownership by individuals 19602922
  2. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 19595127
  3. SC 13G - Statement of acquisition of beneficial ownership by individuals 19576643
  4. 8-K - Current report 19526186
  5. 8-K - Current report 181197066
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181168557
  7. 8-K - Current report 181168131
  8. 8-K - Current report 181166486
  9. 8-K - Current report 181131505
  10. 8-K - Current report 181051269